Azintuxizumab, a innovative monoclonal immunoglobulin, represents a promising advancement in medical care. Its unique mechanism of mode involves selectively binding to the PD-L1 protein, https://www.targetmol.com/compound/azintuxizumab a molecule often overexpr

Osocimab, formerly known as BAY 1213790, represents a unique monoclonal antibody currently in clinical assessment for the management of multiple hematologic malignancies. This agent primarily targets CD38, a surface receptor present on abnormal cells in conditions like multiple myeloma and acute